Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Blood Pressure and Hypertension Studies, Lipoproteins and Cardiovascular Health, Genetic Associations and Epidemiology, and Hormonal Regulation and Hypertension.
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―
Long-Term Incidence of Stroke and Dementia in ASCOT
Lowering systolic blood pressure to 120 mmHg or <i>The Lancet</i>’s true grit
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization in Unselected Individuals
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double‐Blind Randomized Controlled Trial
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
Interpretation of the evidence for the efficacy and safety of statin therapy
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial
Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci
ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data